Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy

KM Garland, TL Sheehy, JT Wilson - Chemical reviews, 2022 - ACS Publications
The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

JD Martin, H Cabral, T Stylianopoulos… - Nature reviews Clinical …, 2020 - nature.com
Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy

X Sun, Y Zhang, J Li, KS Park, K Han, X Zhou… - Nature …, 2021 - nature.com
Nutritional metal ions play critical roles in many important immune processes. Hence, the
effective modulation of metal ions may open up new forms of immunotherapy, termed as …

STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

EL Dane, A Belessiotis-Richards, C Backlund… - Nature Materials, 2022 - nature.com
Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates
antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We …

Rethinking cancer nanotheranostics

H Chen, W Zhang, G Zhu, J **e, X Chen - Nature Reviews Materials, 2017 - nature.com
Advances in nanoparticle synthesis and engineering have produced nanoscale agents
affording both therapeutic and diagnostic functions that are often referred to by the …

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

VP Chavda, LK Vora, AK Pandya, VB Patravale - Drug discovery today, 2021 - Elsevier
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …

Vaccine-like nanomedicine for cancer immunotherapy

Y Yi, M Yu, W Li, D Zhu, L Mei, M Ou - Journal of Controlled Release, 2023 - Elsevier
The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

P Dosta, AM Cryer, MZ Dion, T Shiraishi… - Nature …, 2023 - nature.com
Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Recent advancements in liposome technology

N Filipczak, J Pan, SSK Yalamarty… - Advanced drug delivery …, 2020 - Elsevier
The liposomes have continued to be well-recognized as an important nano-sized drug
delivery system with attractive properties, such a characteristic bilayer structure assembling …

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

D Shae, KW Becker, P Christov, DS Yun… - Nature …, 2019 - nature.com
Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) are a promising
class of immunotherapeutics that activate innate immunity to increase tumour …